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Abstract
Introduction Systemic sclerosis (SSc) is a connective tissue disease characterized by progressive fibrosis of the skin and 
internal organs, leading to their failure and disturbances in the morphology and function of blood vessels. The disease affects 
people in different ways, and identifying how the difficulties and limitations are related to quality of life may contribute to 
designing helpful interventions. The aim of this study was to identify factors associated with quality of life in people with SSc.
Methods This was a cross-sectional study conducted in 11 rheumatic centres in Poland. Patients diagnosed with SSc were 
included. Quality of life was measured using the SSc Quality of Life Questionnaire (SScQoL). The following candidate 
factors were entered in preliminary multivariable analysis: age, place of residence, marital status, occupational status, dis-
ease type, disease duration, pain, fatigue, intestinal problems, breathing problems, Raynaud’s symptoms, finger ulcerations, 
disease severity, functional disability, anxiety and depression. Factors that achieved statistical significance at the 10% level 
were then entered into a final multivariable model. Factors achieving statistical significance at the 5% level in the final model 
were considered to be associated with quality of life in SSc.
Results In total, 231 participants were included. Mean age (SD) was 55.82 (12.55) years, disease duration 8.39 (8.18) years 
and 198 (85.7%) were women. Factors associated with quality of life in SSc were functional disability (β = 2.854, p < 0.001) 
and anxiety (β = 0.404, p < 0.001). This model with two factors (functional disability and anxiety) explained 56.7% of the 
variance in patients with diffuse SSc and 73.2% in those with localized SSc.
Conclusions Functional disability and anxiety are significantly associated with quality of life in SSc. Interventions aimed at 
improving either of these factors may contribute towards improving the quality of life of people with SSc.
Keywords Systemic sclerosis · Quality of life · Physical disability · Anxiety
Introduction
Rheumatic diseases, especially chronic non-infectious arthri-
tis and the so-called systemic connective tissue diseases, 
hold a special place among chronic diseases; they are the 
main cause of organ dysfunction, disability and even disabil-
ity or premature death [1, 2]. Over the last few decades, there 
has been great progress in improving the effectiveness of 
their treatment. At the turn of the century, biological drugs 
have allowed not only to slow down, but, for the first time in 
history, stop the destruction of joints which is the essence of 
inflammatory rheumatic diseases [3]. The exception to this 
is systemic sclerosis (SSc), which is a chronic disease with 
autoimmune background.
SSc is characterized by progressive fibrosis of the skin 
and internal organs, leading to their failure and disturbances 
of morphology and function of blood vessels [4]. SSc is not 
a uniform disease. There are several clinical forms, including 
mainly limited systemic sclerosis (lSSc) and diffuse systemic 
sclerosis (dSSc) [2, 3]. SSc is a rare condition with global 
incidence estimated to be between 3 and 24 per 100,000 
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population. It is higher in North America and Australia com-
pared to Europe and Japan [5]. About 10,000 people live 
with SSc in Poland (1 patient in about 4000 people from the 
entire population). Women are 3 to 5 times more likely than 
men to have SSc. Disease incidence is highest between 35 
and 55 years [2, 3].
Currently, there is no curative treatment or drugs that 
effectively inhibit or at least significantly delay the progres-
sion of the disease. However, in the last few decades, the sur-
vival rate of patients with SSc has been somewhat extended. 
This is the result of the use of organ-specific therapy, based 
on the assumptions of the complexity of therapeutic treat-
ment and the individualization of treatment, taking into 
account the duration of the disease and the advancement of 
organ changes [6].
As a chronic disease, SSc affects patients’ quality of 
life in many ways. Some of the problems include feeling 
tired; limitation of the ability to perform everyday activi-
ties, especially manual ones; unpredictable course of the 
disease, especially the dSSc form; distress related to skin 
and internal organs ailments; sleep disorders; unacceptance 
of change of look of face and general appearance, low self-
esteem; deficit of knowledge about the disease, leading to 
ineffective self-care [7–10].
Health-Related Quality of Life (HRQoL) is defined as 
the influence of the disease and treatment on functioning 
and overall sense of life satisfaction perceived by the patient 
[11]. Improving patients’ quality of life is the mark of a 
holistic approach to address the complex problems of the 
patient with chronic diseases such as reduced tolerance of 
treatment, ineffective therapies or risks associated with co-
morbid diseases. This helps clinicians, nurses and health 
professionals to identify areas that are amenable to change 
in order to improve the patient’s quality of life, alongside 
medical goals [7]. The aim of this study was to determine 
factors associated with quality of life in people with SSc.
Methods
Design
This was a multicentre cross-sectional analytical study car-
ried out in 11 rheumatology centres in Poland. Patients’ 
inclusion criteria were a diagnosis of SSc, based on ACR/
EULAR 2013 classification [12] and ages of 18 years and 
above. The exclusion criterion was the coexistence of 
another known systemic connective tissue disease.
Ethics consideration
The research was carried out in accordance with the Dec-
laration of Helsinki and Good Clinical Practice in research. 
The Bioethics Committee of the Medical University in Bia-
lystok, Poland granted the ethical approval for the study 
(R-I-002/175/2016). Participation was voluntary and par-
ticipants were informed about the project and gave written 
consent.
Measures
To measure quality of life (outcome variable), we used a 
disease-specific measure, the Systemic Sclerosis Quality 
of Life Questionnaire (SScQoL), developed using a needs-
based quality of life model which was validated for Poland 
and 7 other European countries using Rasch analysis [13]. 
The tool has 29 questions divided into five subscales relat-
ing to physical functioning (score range: 0 to 6), emotional 
functioning (0 to 13), social functioning (0 to 6), sleep (0 to 
2) and pain (0 to 2). High scores indicate a greater impact 
of the disease, i.e. decrease of HRQoL [14].
We expected the following factors (explanatory variables) 
to be associated with quality of life in SSc as they repre-
sent some aspects of disease impact: functional disability 
(patients’ difficulty in performing daily activities), pain, 
fatigue, intestinal problems, breathing problems, Raynaud’s 
symptoms, finger ulcerations, patient’s own assessment of 
disease severity and psychological distress. Personal factors 
(age, type of SSc, disease duration, place of residence, mari-
tal status and occupational status) were also considered in 
addition to the above, making a total of 16 candidate factors.
Functional disability was assessed using the Health 
Assessment Questionnaire-Disability Index (HAQ-DI), 
which comprises 20 items divided into 8 sections: dress-
ing and washing, morning rising, eating, walking, personal 
hygiene, lifting, grasping and movement. The total score 
ranges from 0 to 3: the higher the score, the worse the level 
of physical functioning [14, 15]. Based on the Visual Ana-
logue Scale (VAS 0 to 100), the following health problems 
were assessed: pain intensity (pain-VAS), fatigue (fatigue-
VAS), intestinal problems, breathing problems, severity 
of Raynaud’s symptoms, severity of finger ulcerations and 
general evaluation of the disease severity [16]. Psychologi-
cal distress (anxiety and depression) was assessed using the 
Hospital Anxiety and Depression Scale (HADS). The ques-
tionnaire consists of two subscales: anxiety (HADS-A, 0 
to 21) and depression (HADS-D, 0 to 21), each containing 
7 statements. A score of 0 to 7 in each subscale means the 
norm, no disorders; a score of 8 to 10 means suspicion of 
anxiety and/or depressive disorders; score of 11 or higher 
indicates the possibility of anxiety or depression disorders, 
respectively [17]. The participants completed the question-
naires unaided. While the SScQoL measures the impact of 
disease on health and well-being, all the above factors meas-
ure different aspects of disease impact but not comprehen-
sively. They were therefore expected to correlate with the 
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SScQoL, and in our analyses below, we entered all these 
candidate factors into a multivariable model to test which 
ones would independently be associated with SScQoL.
Sample size estimation
As SSc is a rare condition, 11 centres were recruited and 
were asked to invite all eligible patients allowing a 30% 
response rate. We recruited 231 patients and tested the 16 
prespecified candidate factors in a multiple linear regression. 
Post hoc power analysis showed that a sample size of 226 
would achieve power of 97% when including 16 explanatory 
variables and an alpha level of 0.05.
Data analysis
The raw scores from the SScQoL which are ordinal in nature 
were transformed into interval level measures using cali-
brated conversion tables (online supplementary material 1) 
before being combined with other data and subjected to 
parametric analyses. All data were then summarized descrip-
tively using means and standard deviations. To assess dif-
ferences between subgroups of patients with lSSc and dSSc, 
univariable analyses were conducted. To identify factors 
associated with quality of life in SSc, all 16 prespecified fac-
tors (age, type of SSc, disease duration, place of residence, 
marital status, occupational status, pain, fatigue, intestinal 
problems, breathing problems, Raynaud’s symptoms, finger 
ulcerations, disease severity, functional disability, anxiety 
and depression) were entered in a preliminary multivari-
able analysis. Factors that achieved statistical significance 
at the 10% level were then entered into a final multivariable 
model. For these analyses, we present parameter estimates 
(β) with corresponding 95% CIs and p values for factors 
found to be significantly associated with quality of life in 
SSc at the 0.05 alpha level. All data were analysed using 
PQStat v.1.4.2 software.
Results
The characteristics of patients with SSc
In total, 231 patients with SSc participated in the study, 114 
(49.4%) had lSSc and 117 (50.6%) had dSSc. Average (SD) 
age of the participants was 55.82 (12.55) years, disease dura-
tion 8.39 (8.18) years and the majority were women 198 
(85.7%). The majority, 160 (69.3%), of the patients were in 
a relationship/married and 151 (65.4%) were on disability 
pension/retirement. The characteristics of patients are sum-
marized in Table 1.
Differences between patients with dSSc and lSSc
Table 2 presents differences in health problems and qual-
ity of life between the participants with dSSc and those 
with lSSc. Participants with dSSc reported higher levels of 
functional disability, pain, fatigue and self-reported disease 
severity than those with lSSc. Significant differences were 
also observed in relation to the occurrence of finger ulcera-
tion and breathing problems. Patients with dSSc had worse 
quality of life than those with lSSc.
Factors associated with quality of life in people 
with SSc
Table 3 presents the results of the multivariable analyses. 
After fitting all candidate factors into a preliminary mul-
tivariable model, four factors were statistically significant 
at 10% level. These were functional disability (β = 2.939, 
p < 0.001), fatigue severity (β = 0.020, p = 0.036), disease 
severity (β = 0.017, p = 0.096) and anxiety (β = 0.428, 
p < 0.001). When fitting these four factors in the final mul-
tivariable model, only two factors remained statistically 
significant at 5% level. These were functional disability 
Table 1  Characteristics of patients with SSc
lSSc limited systemic sclerosis, dSSc diffuse systemic sclerosis
Variables studied (score range) n (%) Mean (SD)
Age in years 55.82 (12.55)
Gender—number of women 198 (85.7)
Educational background
 Basic 22 (9.5)
 Professional 61 (26.4)
 Secondary 95 (41.1)
Higher education 53 (22.9)
Place of residence
 Urban (> 100,000) 85 (36.8)
 Urban (up to 100,000) 72 (31.2)
 Rural 74 (32.0)
Marital status
 In a relationship/married 160 (69.3)
 Single 71 (30.7)
Occupational status
 High school student/college student 7 (3.0)
 Employed 57 (24.7)
 Unemployed 16 (6.9)
 Person on the disability allowance/
retired
151 (65.4)
Clinical form systemic sclerosis (SSc)
 lSSc 114 (49.4)
 dSSc 117 (50.6)
 Disease duration in years 8.39 (8.18)
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Table 2  Difference in health problems and quality of life between patients with dSSc and lSSc
Bold value indicates the level of significance p ≤ 0.05
lSSc limited systemic sclerosis, dSSc diffuse systemic sclerosis, HAQ-DI Health Assessment Questionnaire-Disability Index, VAS Visual Ana-
logue Scale, SScQoL Systemic Sclerosis Quality of Life Questionnaire
Variables studied (score range) Total patients n = 231 Clinical form of SSc Difference between groups
lSSc
n = 114
dSSc
n = 117
Mean (SD) Mean (SD) Mean (SD) F statistic (p value)
HAQ-DI (0–3) 0.99 (0.75) 0.83 (0.73) 1.15 (0.74) 11.06 (0.001)
Pain-VAS (0–100) 33.08 (28.36) 29.26 (27.86) 36.80 (28.46) 4.14 (0.043)
Fatigue-VAS (0–100) 43.00 (29.04) 38.56 (30.20) 47.33 (27.30) 5.37 (0.021)
Disease severity (0–100) 41.32 (27.10) 35.79 (28,41) 46.71 (24.71) 9.73 (0.002)
Raynaud’s attacks (0–100) 38.10 (31.90) 34.12 (31.51) 41.97 (31.94) 3.53 (0.062)
Intestinal problems (0–100) 20.18 (27.73) 17.68 (25.60) 22.62 (29.55) 1.85 (0.186)
Breathing problems (0–100) 26.57 (27.59) 22.32 (26.38) 30.71 (28.22) 5.44 (0.021)
Finger ulceration (0–100) 17.50 (27.85) 12.94 (25.07) 22.03 (29.77) 6.24 (0.013)
HADS-A (0–21) 8.96 (4.67) 8.68 (5.03) 9.22 (4.28) 0.77 (0.382)
HADS-D (0–21) 6.70 (4.12) 6.44 (4.47) 6.96 (3.74) 0.92 (0.340)
SscQoL (0–29) 14.81 (5.08) 13.89 (5.56) 15.71 (4.40) 7.58 (0.006)
SscQoL (domains)
 Physical functioning (0–6) 3.66 (1.57) 3.40 (1.59) 3.91 (1.51) 6.29 (0.013)
 Emotional functioning (0–13) 6.43 (3.04) 6.03 (3.27) 6.82 (2.75) 3.94 (0.048)
 Social functioning (0–6) 2.25 (1.87) 1.84 (1.79) 2.65 (1.85) 11.59 (0.001)
 Sleep (0–2) 0.96 (0.91) 0.85 (0.92) 1.07 (0.89) 3.33 (0.069)
 Pain (0–2) 0.98 (0.84) 0.82 (0.83) 1.14 (0.82) 8.25 (0.004)
Table 3  Factors associated with quality of life in SSc—results of multivariable analyses
HAQ-DI Health Assessment Questionnaire-Disability Index, HADS-A Hospital Anxiety and Depression Scale-Anxiety subscale, HADS-D Hos-
pital Anxiety and Depression Scale-Depression subscale
Bold variables denote significant factors associated with quality of life in SSc
Variables Preliminary multivariable analysis Final multivariable analysis
Parameter estimate 
(factor β)
95% CI p value Parameter estimate 
(factor β)
95% CI p value
Age in years − 0.006 − 0.037 to 0.024 0.683
Type of SSc 0.165 − 0.494 to 0.825 0.622
Disease duration in years 0.012 − 0.029 to 0.054 0.565
Place of residence 0.285 − 0.110 to 0.680 0.156
Family situation 0.149 − 0.119 to 0.418 0.274
Occupational status − 0.048 − 0.460 to 0.364 0.818
HAQ-DI 2.939 2.272 to 3.605 < 0.001 2.854 5.745 to 3.403 < 0.001
Pain − 0.001 − 0.022 to 0.019 0.895
Fatigue 0.020 0.001 to 0.040 0.036 0.014 − 0.002 to 0.031 0.082
Disease Severity 0.017 − 0.003 to 0.038 0.096 0.016 − 0.001 to 0.033 0.070
Raynaud’s attacks − 0.008 − 0.022 to 0.005 0.225
Intestinal problems − 0.006 − 0.021 to 0.008 0.400
Breathing problems 0.006 − 0.010 to 0.022 0.444
Finger ulceration 0.003 − 0.011 to 0.017 0.690
HADS-A 0.428 0.313 to 0.543 < 0.001 0.404 0.326 to 0.482 < 0.001
HADS-D − 0.009 − 0.145 to 0.127 0.896
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(β = 2.854, p < 0.001) and anxiety (β = 0.404, p < 0.001). The 
results suggest that a model with two factors (functional dis-
ability and anxiety) explained 56.7% of the variance in dSSc 
and 73.2% in lSSc and was a significant factor associated 
with quality of life in people with the two clinical forms of 
SSc.
Discussion
To our knowledge, this is the first time the SScQoL has been 
used to assess quality of life of people with SSc in a large 
population. A smaller study recently conducted in Sweden 
(n = 67) [18] showed that the SScQoL had a better ability 
to capture the disease-specific factors influencing quality 
of life in SSc than the generic measure of quality of life 
EQ 5D. Cross-cultural validation of the SScQoL into Pol-
ish was part of an international collaboration [13] and this 
allows the measure to be used in multinational research and 
cross-cultural comparisons. The key findings of our study 
are that functional disability (limitations of physical func-
tion) and anxiety are significantly associated with quality of 
life in people with SSc (dSSc and lSSc). These two factors 
are amenable to change and therefore can be a target for 
non-pharmacological interventions by health professionals.
The above results are supported by previous studies. An 
Italian study by Danieli et al. [9] using SF36 showed that 
limitations in the ability to perform daily activities were 
the main reason for poor HRQoL in patients with SSc [9]. 
According to Sandqvist et al., [19] the difficulties in per-
forming activities involve mainly manual abilities such as 
eating, drinking, washing and dressing. Other studies indi-
cate that the symptom of “tight glove” characteristic for 
SSc (painful cracks and sores of the fingers, making it dif-
ficult to perform precise tasks) may limit the professional 
and social activity of patients, causing stress and as a result 
lowering the quality of life [20, 21]. Non-pharmacological 
interventions by occupational therapists may help address 
some aspects of functional disability, by providing adapta-
tions and skills to help patients to be independent and live 
as normal a life as possible. Our findings also suggest that 
anxiety is a significant factor associated with quality of 
life in SSc. Anxiety disorders are a significant problem for 
people with SSc (affecting over 80% of participants in our 
study) and correlate positively with depression [22]. In our 
study, almost half of the participants had HADS-A scores 
suggesting a suspected or moderate anxiety disorder, and 
more than a third suspected or moderate severity of depres-
sive disorders. Anxiety has been shown to be associated with 
other long-term conditions such as diabetes and rheumatoid 
arthritis. Whether the anxiety in SSc is generalized or dis-
ease specific, interventions to address anxiety are likely to 
help improve quality of life in people with SSc.
Analysis of the results by clinical presentations showed 
that health problems (ulceration of the fingers, disability, 
dyspnoea, fatigue, pain) were more severe in the dSSc 
and consequently quality of life in patients with dSSc was 
worse than those with lSSc. While this finding is interest-
ing, disease type in the multivariable analyses was not 
shown to be an independent factor associated with quality 
of life. This suggests that interventions to improve quality 
of life should be targeted to both disease types equally.
Although other factors were not shown to be signifi-
cantly associated with quality of life in SSc, it is important 
to note that they may pose problems in the lives of people 
with SSc. One of these factors is finger (digital) ulcers 
which are very painful, difficult to treat and severely limit 
activities of daily living. Although very few patients with 
finger ulceration were represented, these pose a signifi-
cant burden on people with SSc. Fatigue also is a com-
mon problem in people with rheumatic diseases, having 
a physical, psychological as well as a social dimension 
[7, 8]. Fatigue can be a significant cause of suffering and 
disability in people with SSc [23]. There is a complex 
association between fatigue, pain and physical function-
ing. Pain has been shown to be strongly associated with 
fatigue, depression and diminished physical functioning 
[21, 24–31]. Previous studies have shown that pain, finger 
ulcerations, Raynaud’s symptoms and the involvement of 
internal organs, especially the lungs, make it difficult to 
perform everyday tasks and may also limit social func-
tioning [8, 29–31]. The severity of the disease may be 
associated with the risk of emotional problems [8] and 
this has been evidenced in our study. Depression affects 
the physical as well as the psychological quality of life [32, 
33]. Benrud-Larson et al., [34] reported that organ changes 
in the course of SSc, as well as physical limitations, hinder 
social adaptation and may predispose patients to depres-
sion. Also, shiny, tense, thickened skin, telangiectasias and 
microstomia cause aesthetic changes to the face, which 
causes dissatisfaction, reduced self-esteem, deepening 
depression and limited psycho-social functioning of peo-
ple with SSc [35, 36]. Family relationships and place of 
residence may also play a role in patients’ quality of life. 
For example, people with SSc who are also caring for their 
partner or loved ones may have additional responsibilities 
that may affect their self-care and quality of life.
The interest in addressing quality of life in people with 
scleroderma emanates from a holistic approach to care for 
patients with chronic, inflammatory and connective tissue 
diseases, which is at the heart of rheumatology nursing. Self-
reported HRQoL informs about disease impact and how the 
patient is coping with new challenges and problems that 
affect health, social status or psychological functioning [1, 
37]. Monitoring of quality of life is an important element of 
managing the condition and may help to inform appropriate 
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interventions, which are likely to be non-pharmacological 
and delivered by the multidisciplinary team [38–40].
Our research has two key limitations. First, the partici-
pants in the study were those who were attending a medi-
cal facility, meaning that selection bias cannot be excluded. 
However, as SSc is a rare condition and this study was 
conducted in 11 sites in Poland, including 231 participants 
(approx. 10,000 people with the condition) provides fairly 
generalizable results for the population with the condition in 
Poland [2, 3]. Second, the study was cross-sectional, there-
fore no causality can be ascribed to the identified factors 
associated with quality of life in SSc. However, identifying 
these factors is important as it may help direct the design of 
important interventions.
Conclusion
Our study has identified functional disability and anxiety 
to be the main factors associated with quality of life in peo-
ple with SSc. The overall aim of disease management is to 
improve quality of life in people with SSc. Identification of 
these factors will help design appropriate non-pharmacolog-
ical interventions, delivered by a multidisciplinary team. Our 
results also demonstrate that SScQoL captures important 
disease-specific factors associated with quality of life in SSc 
and is therefore a useful tool for clinical and research use.
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